Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: DataM Intelligence | PRODUCT CODE: 1058851

Cover Image

PUBLISHER: DataM Intelligence | PRODUCT CODE: 1058851

Global Prostate Specific Antigen Testing Market - 2021-2028

PUBLISHED:
PAGES: 180 Pages
DELIVERY TIME: 2 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4350
PDF & Excel (Multiple User License)
USD 4850
PDF & Excel (Enterprise License)
USD 7850

Add to Cart

Market Overview

The Global "Prostate Specific Antigen Testing Market" is Predicted to grow at a CAGR of 4% during the forecast period (2021-2028).

Prostate specific antigen (PSA) is a protein that is only secreted by prostatic epithelial cells and is a valuable tumor marker for prostate cancer. Though not a prostate-specific molecule, its elevated presence in blood serum is used to screen men for prostate cancer. Increased PSA levels are linked to prostatitis, an inflammation of the prostate gland, or a benign form of prostatic hyperplasia. PSA testing is used with a digital rectal exam (DRE) to screen asymptomatic men for prostate cancer. PSA screening has grown in popularity among clinicians and healthcare providers to detect potential cases of prostate cancer and assist them in determining the nature of the problem.

Market Dynamics

Due to the growing senior population, the market for prostate-specific antigen testing is booming. Increased public awareness about the benefits of prostate cancer screening, technological advancements in testing and treating prostate cancer, and various reimbursement policies for prostate cancer treatments in various developed and developing regions influence the growth of the prostate-specific antigen market.

The increase in prevalance of prostate cancer in the market will drive the market growth

The global prostate-specific antigen testing market is being driven primarily by the rising incidence of prostate cancer among men, particularly those over 50. Furthermore, after prostate cancer treatment, PSA levels must be monitored regularly.

In addition, the use of serum-based biomarkers for the diagnosis of prostate cancer has increased the demand for PSA testing. When combined with an array of advanced cancer-specific markers, PSA testing has increased the accuracy and specificity of the results, boosting the market.

However, overdiagnosis of clinically insignificant prostate cancer, combined with exaggeration of the results, is a major deterrent to the use of prostate-specific antigen testing. Several reimbursement policies in developed and developing countries cover annual PSA testing for men over 50. Furthermore, PSA testing as part of annual wellness coverage in developed countries such as the United States is expected to create promising opportunities for market players.This contributes to the growth of the Global Prostate Specific Antigen Testing market.

False-positive or false-negative PSA test results is likely to hamper the market growth

Because of false-positive or false-negative PSA test results, the prostate-specific antigen testing market is facing some challenges. Furthermore, most of these tests, such as PSA screening, had several side effects, such as difficulties in urine flow, effects on bowel function, erectile dysfunction, and frequent pains, which hampered the growth of the Prostate-specific antigen testing market. Higher technological advancements that result in the most simplified and accurate results in tests such as the Prostate Health Index (phi) can limit the growth of the PSA testing market unless the way the tests are treated changes.

COVID-19 Impact Analysis

Manufacturers swiftly adjust their company practices and purchasing techniques to satisfy market demand as the COVID-19 problem worsens. Because the virus has spread over the globe, individuals are focusing more on their health and building immunity. PSA testing is a preventative measure for detecting prostate cancer early, and it will be in high demand during the predicted period. However, because it is not a life-or-death screening, it may take a backseat as the medical community deals with COVID-related emergencies.

Segment Analysis

The biopsy segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)

Over the projection period, the biopsy segment is expected to grow rapidly. The rising number of operations, the rising number of prostate cancer cases, and the rising geriatic population contribute to the segment's growth. For instance, except for skin cancer, prostate cancer is the most common cancer in men. An estimated 248,530 men in the United States are diagnosed with prostate cancer this year according to cancer net. According to Cancer.org , Prostate cancer affects about 1 in every 8 men at some point in their lives.Older males and non-Hispanic Black men are more prone to acquire prostate cancer. Men over the age of 65 account for about 6 out of every 10 occurrences, whereas men under 40 are extremely rare. Men are diagnosed at an average age of 66.

Furthermore, several reimbursements and medical policies for prostate cancer treatments in various developing and developed regions may impact the growth of the biopsy segment during the forecast period.

Geographical Analysis

North America region holds the largest market share of global prostate specific antigen testing market

PSA testing is a popular service in North America. The rising incidence of prostate cancer and the resulting high mortality rate in the region's developed nations are driving the high demand for PSA screening. According to the American Society of Clinical Oncology (ASCO), prostate cancer is the second leading cause of death in men with cancer in the United States. Furthermore, advancements in healthcare and increased government focus on prostate cancer detection are expected to fuel the regional market. Furthermore, the presence of many key players in North America is a major factor driving market growth.

Asia-Pacific prostate specific antigen testing is growing at the fastest CAGR during the forecast period, owing to increased healthcare spending and increased awareness of prostate cancer and the preference for PSA testing as a first-line test for a repeat screening. Other factors that contribute to the market's growth include a large patient base of various chronic diseases such as prostate cancer, which contribute to the growth of the prostate specific antigen testing market.

Competitive Landscape

The prostate specific antigen testing market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Merck and Co.,Siemens Healthcare, DiaSorin, Roche, Beckman Coulter, Mediwatch(LABORIE),Bodi Tech,Bristol-Myers Squibb Company, GE Healthcare , Endocare ,GlaxoSmith Kline,Anixa Biosciences, Ortho Clinical,Fujirebio, Pharmacia Delfia., Medtronic Plc.

Some of the major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the blood and blood products market globally. For instance on December 29th, 2019, Anixa Biosciences, Inc. commercialized the Cchek Prostate Cancer Confirmation test (Cchek PCC), which detects prostate cancer using AI, artificial intelligence, liquid-biopsy technology, and flow cytometry.

Key Developments

In Feb 2019,Premarket approval has been granted to OPKO Diagnostics for a prostate-specific antigen (PSA) test that provides results at the point of care.

In July 2019,MDNA Life Sciences, a diagnostics developer, has partnered with Aspire Pharma to bring the new Mitomic Prostate Test (MPT) to clinical use in the United Kingdom.

Cleveland Diagnostics

Overview: Cleveland Diagnostics is a diagnostics company developing highly effective, low-cost diagnostic tests to improve cancer detection.

Product Portfolio:

IsoPSA Assay: Cleveland Diagnostics has received breakthrough device designation from the US Food and Drug Administration (FDA) for its IsoPSA Assay, which detects prostate cancer. IsoPSA is a blood-based, non-invasive assay that examines the structural changes in prostate-specific antigen (PSA), the current gold standard for prostate cancer detection.

Why Purchase the Report?

Visualize the composition of the global prostate specific antigen testing market segmentation by test types, application, assay type, end user, and region highlighting the key commercial assets and players.

Identify commercial opportunities in global prostate specific antigen testing market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global prostate specific antigen testing market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The Global Prostate Specific Antigen Testing market report would provide an access to an approximately 40+ market data table, 45+ figures and 180 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Market Segmentation

Global Prostate Specific Antigen Testing Market- By Test type

Total Prostate Specific Antigen Test

Complex Prostate Specific Antigen Test

Free Prostate Specific Antigen Test

Prostate Specific Antigen Reverse Transcription Polymerase Chain Reaction Test

Trans-rectal Ultrasound

Biopsy

Global Prostate Specific Antigen Testing Market- By Application

Screening

Post -treating monitoring

Others

Global Prostate Specific Antigen Testing Market- By Assay Type

Radioimmunoassay

Enzyme immunoassay

Global Prostate Specific Antigen Testing Market- By End User

Hospitals

Clinics

Diagnostic Centers

Research institute

Others

Global Prostate Specific Antigen Testing Market- By Region

North America

Europe

Asia-Pacific

Middle East & Africa

South America

Product Code: DMCD4666

Table of Contents

1. Global Prostate Specific Antigen Testing Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Prostate Specific Antigen Testing Market- Market Definition and Overview

3. Global Prostate Specific Antigen Testing Market- Executive Summary

  • 3.1. Market Snippet by Test Type
  • 3.2. Market Snippet by Application
  • 3.3. Market Snippet by Assay Type
  • 3.4. Market Snippet by End User
  • 3.5. Market Snippet by Region

4. Global Prostate Specific Antigen Testing market- Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising prevalence of prostate cancer
      • 4.1.1.2. Technological advancement
    • 4.1.2. Restraints:
      • 4.1.2.1. False positive or false negative PSA test results.
      • 4.1.2.2. Development of alternative methods.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Prostate Specific Antigen Testing Market- Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis

6. Global Prostate Specific Antigen Testing Market- COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Prostate Specific Antigen Testing Market- By Types

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type Segment
    • 7.1.2. Market Attractiveness Index, By Test Type Segment
  • 7.2. Total Prostate Specific Antigen Test*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Complex Prostate Specific Antigen Test
  • 7.4. Free Prostate Specific Antigen Test
  • 7.5. Prostate Specific Antigen Reverse Transcription Polymerase Chain Reaction Test
  • 7.6. Trans-rectal Ultrasound
  • 7.7. Biopsy

8. Global Prostate Specific Antigen Testing Market- By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Screening*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Post-treating monitoring
  • 8.4. Others

9. Global Prostate Specific Antigen Testing Market- By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User Segment
  • 9.2. Hospitals *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Clinics
  • 9.4. Diagnostic Centers
  • 9.5. Research Institute
  • 9.6. Others

10. Global Prostate Specific Antigen Testing Market- By Region

  • 10.1. Introduction
  • 10.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
  • 10.3. Market Attractiveness Index, By Region
  • 10.4. North America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Assay Type
    • 10.4.6. Market Size Analysis ,and Y-o-Y Growth Analysis (%), By End User
      • 10.4.6.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.2. U.S.
      • 10.4.6.3. Canada
      • 10.4.6.4. Mexico
  • 10.5. Europe
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Assay Type
    • 10.5.6. Market Size Analysis ,and Y-o-Y Growth Analysis (%), By End User
    • 10.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. Germany
      • 10.5.7.2. U.K.
      • 10.5.7.3. France
      • 10.5.7.4. Italy
      • 10.5.7.5. Spain
      • 10.5.7.6. Rest of Europe
  • 10.6. South America
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Assay Type
    • 10.6.6. Market Size Analysis ,and Y-o-Y Growth Analysis (%), By End User
    • 10.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.6.7.1. Brazil
      • 10.6.7.2. Argentina
      • 10.6.7.3. Rest of South America
  • 10.7. Asia Pacific
    • 10.7.1. Introduction
    • 10.7.2. Key Region-Specific Dynamics
    • 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Assay Type
    • 10.7.6. Market Size Analysis ,and Y-o-Y Growth Analysis (%), By End User
    • 10.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.7.7.1. China
      • 10.7.7.2. India
      • 10.7.7.3. Japan
      • 10.7.7.4. Australia
      • 10.7.7.5. Rest of Asia Pacific
  • 10.8. Middle East and Africa
    • 10.8.1. Introduction
    • 10.8.2. Key Region-Specific Dynamics
    • 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Assay Type
    • 10.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Global Prostate Specific Antigen Testing Market- By Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Global Prostate Specific Antigen Testing Market- By Company Profiles

  • 12.1. Cleveland Diagnostics*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Abbott
  • 12.3. Siemens Healthcare
  • 12.4. DiaSorin
  • 12.5. Roche
  • 12.6. Beckman Coulter
  • 12.7. Mediwatch(LABORIE)
  • 12.8. Bodi Tech
  • 12.9. Bristol-Myers Squibb Company
  • 12.10. GE Healthcare
  • 12.11. Endocare
  • 12.12. GlaxoSmith Kline
  • 12.13. Anixa Biosciences
  • 12.14. Ortho Clinical
  • 12.15. Fujirebio
  • 12.16. Pharmacia Delfia
  • 12.17. Merck & Co

LIST NOT EXHAUSTIVE

13. Global Prostate Specific Antigen Testing Market- By DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!